Last checked at 9 Feb 2018 11:57
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Issue of options and directors dealings
London, UK., 9 February 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces it has awarded options to directors and key management. The options may be exercised at a price of 4 pence per share at any time up until 7 February 2028.
Name of Director | Number of Existing Options* | Option Award | Total number of Options | % of existing share capital |
Oliver de Giorgio-Miller | 555,000 | 2,750,000 | 3,305,000 | 0.8% |
Dr Satu Vainikka | 694,000 | 3,625,000 | 4,319,000 | 1.1% |
Dr George Morris | 597,000 | 3,125,000 | 3,722,000 | 0.9% |
Gerry Desler | 592,960 | 3,000,000 | 3,592,960 | 0.9% |
Kevin Alexander | 545,000 | 2,500,000 | 3,045,000 | 0.7% |
Others | 429,000 | 2,300,000 | 2,279,000 | 0.6% |
Total | 3,412,960 | 17,300,000 | 20,712,960 | 5.0% |
*existing options are exercisable at a price between 43.125p - 125p
The issued share capital of the Company comprises 407,462,717 ordinary shares of 0.1 pence per shares. The table below illustrates the existing equity holdings of the directors:
Name of Director | Total number of shares | % of existing share capital |
Oliver de Giorgio-Miller | 59,555 | 0.015% |
Dr Satu Vainikka | 624,909 | 0.15% |
Dr George Morris | 588,287 | 0.14% |
Gerry Desler | 541,875 | 0.13% |
Kevin Alexander | 104,278 | 0.026% |
Total | 1,918,904 | 0.46% |
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Richard Nash | Tel: +44 (0) 20 7213 0880 |
Beaufort Securities Limited (Broker) Jon Belliss | Tel: +44 (0) 207 382 8300 |
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Oliver de Giorgio-Miller | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | ValiRx Plc | |||||
b. | LEI | 213800VQKB9SJCQDET40 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over ordinary shares
ISIN: GB00BWWYSP41 | |||||
b. | Nature of the transaction | Grant of options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
4p | 2,750,000 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
2,750,000
4p | |||||
e. | Date of the transaction | 9 February 2018 | |||||
f. | Place of the transaction | AIM | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Dr Satu Vainikka | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | ValiRx Plc | |||||
b. | LEI | 213800VQKB9SJCQDET40 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over ordinary shares
ISIN: GB00BWWYSP41 | |||||
b. | Nature of the transaction | Grant of options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
4p | 3,625,000 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
3,625,000
4p | |||||
e. | Date of the transaction | 9 February 2018 | |||||
f. | Place of the transaction | AIM | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Dr George Morris | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | ValiRx Plc | |||||
b. | LEI | 213800VQKB9SJCQDET40 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over ordinary shares
ISIN: GB00BWWYSP41 | |||||
b. | Nature of the transaction | Grant of options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
4p | 3,125,000 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
3,125,000
4p | |||||
e. | Date of the transaction | 9 February 2018 | |||||
f. | Place of the transaction | AIM | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Gerry Desler | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | ValiRx Plc | |||||
b. | LEI | 213800VQKB9SJCQDET40 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over ordinary shares
ISIN: GB00BWWYSP41 | |||||
b. | Nature of the transaction | Grant of options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
4p | 3,000,000 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
3,000,000
4p | |||||
e. | Date of the transaction | 9 February 2018 | |||||
f. | Place of the transaction | AIM | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Kevin Alexander | |||||
2 | Reason for notification | ||||||
a. | Position/Status | Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | ValiRx Plc | |||||
b. | LEI | 213800VQKB9SJCQDET40 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over ordinary shares
ISIN: GB00BWWYSP41 | |||||
b. | Nature of the transaction | Grant of options | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) per share | Volume(s) | ||||||
4p | 2,500,000 | ||||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
2,500,000
4p | |||||
e. | Date of the transaction | 9 February 2018 | |||||
f. | Place of the transaction | AIM | |||||